These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9073540)

  • 1. Effect of late modulation of nitric oxide production on murine lupus.
    Oates JC; Ruiz P; Alexander A; Pippen AM; Gilkeson GS
    Clin Immunol Immunopathol; 1997 Apr; 83(1):86-92. PubMed ID: 9073540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase.
    Reilly CM; Farrelly LW; Viti D; Redmond ST; Hutchison F; Ruiz P; Manning P; Connor J; Gilkeson GS
    Kidney Int; 2002 Mar; 61(3):839-46. PubMed ID: 11849435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine.
    Weinberg JB; Granger DL; Pisetsky DS; Seldin MF; Misukonis MA; Mason SN; Pippen AM; Ruiz P; Wood ER; Gilkeson GS
    J Exp Med; 1994 Feb; 179(2):651-60. PubMed ID: 7507509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice.
    Oates JC; Gilkeson GS
    J Investig Med; 2004 Jan; 52(1):62-71. PubMed ID: 14989372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis.
    Njoku CJ; Patrick KS; Ruiz P; Oates JC
    J Investig Med; 2005 Nov; 53(7):347-52. PubMed ID: 16297360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis.
    Gilkeson GS; Mashmoushi AK; Ruiz P; Caza TN; Perl A; Oates JC
    PLoS One; 2013; 8(5):e64650. PubMed ID: 23741359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
    Lui SL; Tsang R; Wong D; Chan KW; Chan TM; Fung PC; Lai KN
    Lupus; 2002; 11(7):411-8. PubMed ID: 12195781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2.
    Gilkeson GS; Mudgett JS; Seldin MF; Ruiz P; Alexander AA; Misukonis MA; Pisetsky DS; Weinberg JB
    J Exp Med; 1997 Aug; 186(3):365-73. PubMed ID: 9236188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice.
    Keng T; Privalle CT; Gilkeson GS; Weinberg JB
    Mol Med; 2000 Sep; 6(9):779-92. PubMed ID: 11071272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.
    Yu CC; Yang CW; Wu MS; Ko YC; Huang CT; Hong JJ; Huang CC
    J Lab Clin Med; 2001 Jul; 138(1):69-77. PubMed ID: 11433230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene.
    Njoku C; Self SE; Ruiz P; Hofbauer AF; Gilkeson GS; Oates JC
    J Investig Med; 2008 Oct; 56(7):911-9. PubMed ID: 18797415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
    Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mononuclear phagocyte system dysfunction in murine SLE: abnormal clearance kinetics precede clinical disease.
    Meryhew NL; Shaver C; Messner RP; Runquist OA
    J Lab Clin Med; 1991 Mar; 117(3):181-93. PubMed ID: 2002275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a nitric oxide synthase inhibitor on pressor response to angiotensin II in conscious rats.
    Maeda T; Yoshimura T; Ohshige A; Koyama H; Ito M; Okamura H
    Artery; 1998; 23(1):1-9. PubMed ID: 10846613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide as an inflammatory mediator in autoimmune MRL-lpr/lpr mice.
    Weinberg JB
    Environ Health Perspect; 1998 Oct; 106 Suppl 5(Suppl 5):1131-7. PubMed ID: 9788887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis.
    Oates JC; Halushka PV; Hutchison FN; Ruiz P; Gilkeson GS
    Am J Med Sci; 2011 Feb; 341(2):101-5. PubMed ID: 20924284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of the septic vasculature to prolonged vasopressor therapy with N(omega)-monomethyl-L-arginine and epinephrine in canines.
    Freeman BD; Zeni F; Banks SM; Eichacker PQ; Bacher JD; Garvey EP; Tuttle JV; Jurgensen CH; Natanson C; Danner RL
    Crit Care Med; 1998 May; 26(5):877-86. PubMed ID: 9590318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-beta1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice.
    Yang CW; Yu CC; Ko YC; Huang CC
    Clin Exp Immunol; 1998 Aug; 113(2):258-64. PubMed ID: 9717976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice.
    Xiao ZY; Chen SH; Cheng JP; Zhou WX; Zhang YX; Yang RF; Yun LH
    Arthritis Res Ther; 2012 Nov; 14(6):R235. PubMed ID: 23116248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral administration of malathion on the course of disease in MRL-lpr mice.
    Rodgers KE
    J Autoimmun; 1997 Aug; 10(4):367-73. PubMed ID: 9237800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.